Abpro Holdings, Inc.
Abpro Holdings, Inc., a biotechnology company, focuses on novel antibody constructs for immuno-oncology and ophthalmology. Its platforms include DiversImmune, a discovery platform that generates a diverse collection of proprietary antibodies against clinically validated and novel targets; and MultiMab, an engineering platform that provides the flexibility to combine antibody building blocks in di… Read more
Abpro Holdings, Inc. (ABP) - Net Assets
Latest net assets as of September 2025: $-15.60 Million USD
Based on the latest financial reports, Abpro Holdings, Inc. (ABP) has net assets worth $-15.60 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.70 Million) and total liabilities ($17.30 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-15.60 Million |
| % of Total Assets | -915.74% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Abpro Holdings, Inc. - Net Assets Trend (2016–2024)
This chart illustrates how Abpro Holdings, Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Abpro Holdings, Inc. (2016–2024)
The table below shows the annual net assets of Abpro Holdings, Inc. from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-14.95 Million | +82.44% |
| 2023-12-31 | $-85.14 Million | -12.41% |
| 2022-12-31 | $-75.73 Million | -2566.10% |
| 2021-12-31 | $3.07 Million | +113.67% |
| 2017-12-31 | $-22.46 Million | -81.98% |
| 2016-12-31 | $-12.35 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Abpro Holdings, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9948400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.00K | % |
| Other Components | $100.60 Million | % |
| Total Equity | $-15.49 Million | 100.00% |
Abpro Holdings, Inc. Competitors by Market Cap
The table below lists competitors of Abpro Holdings, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TONGDA GRP HLDGS
MU:TJC
|
$2.00 Million |
|
Vivakor Inc
NASDAQ:VIVK
|
$2.00 Million |
|
Tarachi Gold Corp
OTCQB:TRGGF
|
$2.00 Million |
|
Lowland Investment Co
LSE:LWI
|
$2.00 Million |
|
AVI Japan Opportunity Trust PLC
LSE:AJOT
|
$2.00 Million |
|
SPACEANDPEOPLE LS-1
F:RWK0
|
$2.00 Million |
|
TREVI - Finanziaria Industriale S.p.A.
LSE:0G91
|
$1.99 Million |
|
GeoVax Labs Inc
NASDAQ:GOVX
|
$1.99 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Abpro Holdings, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -85,684,000 to -15,495,000, a change of 70,189,000.
- Net loss of 7,232,000 reduced equity.
- New share issuances of 10,361,000 increased equity.
- Other factors increased equity by 67,060,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-7.23 Million | -46.67% |
| Share Issuances | $10.36 Million | +66.87% |
| Other Changes | $67.06 Million | +432.78% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Abpro Holdings, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $-31.82 | $6.75 | x |
| 2017-12-31 | $-57.28 | $6.75 | x |
| 2021-12-31 | $8.16 | $6.75 | x |
| 2022-12-31 | $-245.76 | $6.75 | x |
| 2023-12-31 | $-274.72 | $6.75 | x |
| 2024-12-31 | $-49.46 | $6.75 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Abpro Holdings, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3951.91%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-97.38%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | -327.24% | 0.22x | 0.00x | $-4.28 Million |
| 2017 | 0.00% | -561.43% | 0.13x | 0.00x | $-10.11 Million |
| 2021 | -584.26% | -3069.79% | 0.06x | 3.13x | $-14.99 Million |
| 2022 | 0.00% | -848.45% | 0.17x | 0.00x | $-9.59 Million |
| 2023 | 0.00% | -9595.08% | 0.04x | 0.00x | $-3.14 Million |
| 2024 | 0.00% | -3951.91% | 0.04x | 0.00x | $-5.68 Million |
Industry Comparison
This section compares Abpro Holdings, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $68,143,821
- Average return on equity (ROE) among peers: -379.10%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Abpro Holdings, Inc. (ABP) | $-15.60 Million | 0.00% | N/A | $2.00 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |